- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03232710
Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition
A Single-dose, Two-treatment, Two-sequence, Two-period, Two Way Crossover Bioequivalence Study of Bosiqing Aripiprazole Orally Disintegrating Tablets and ABILIFY Under Fasting/Fed Condition
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Xiang Jin
- Phone Number: +83-13880932568
- Email: 11679295@qq.com
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610000
- Recruiting
- West China Hospital of Sichuan University
-
Contact:
- Xiang Jin
- Email: 11679295@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects willing to adhere to the protocol requirements and to provide written informed consent.
- Subjects aged between 45 and 65 years,healthy male and non-pregnant, non breast feeding female.
- Subjects' weight within clinically acceptable normal range according to normal values for Body Mass Index (19.00 to 26.00 kg/m2) with minimum of 50 kg weight for male, and minimum of 45 kg weight for female.
- No medical history of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder.
Exclusion Criteria:
1)Subjects with family history of muscular dystonia or the subject has had the drug source dystonia.
2)Subject with history of a asthma. 3)Subject with any (acute or chronic) history of mental illness or have family history of mental illness.
4)Subject have alzheimer's or alzheimer's disease. 5)Subject was hospitalized within 60 days prior to the first dose of the study drug 6)Subject smoking more than five cigarettes within 1 month prior to the first dose study drug.
7)History or presence of significant easy bruising or bleeding 8)History or presence of drug abuse. 9)History of allergic reactions. 10)History or presence of taking psychotropic drugs。 11)Subjects having positive urine screen for drugs of abuse including Methamphetamine, MDMA, ketamine, morphine, heroin.
12)Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 3 weeks prior to Period 01 dosing.
13)Consumption of hypericum perforatum containing products and grapefruit or grapefruit juice from 72 hours prior admission to 3 days after trail end.
14)Subject involved other clinical trials of drugs within 3 months prior to period 01 dosing.
15)Subject with abnormal laboratory tests and diagnosed by physicians as clinically significant 17)Abnormal vital signs test for any one or more:
Abnormal blood pressure:
- Systolic pressure is lower than 80mmHg and/or diastolic pressure down to 40mmHg in sitting position.
- Systolic pressure is higher than 140mmHg and/or diastolic pressure higher than 90mmHg in sitting position.
Abnormal cardiac rate:
- cardiac rate lower than 50
cardiac rate higher than 50 18)Blood alcohol test values≥10mg/dL 19)Volunteer who have donated blood components within 2 weeks prior to the first dose or donated blood (more than 200 ml within 4 weeks; more than 400 ml within 60 days) prior to the first dose; Volunteer who plan to donate blood during the study or 4 weeks after study; Volunteer who lost blood (more than 50ml within 7days or more than 400ml within 30 days) for surgery.
20)Subjects not willing to follow approved birth control methods for the duration of the study 21)ubjects having positive Serum β-hCG test. 22)Subjects plan to donate sperm during study period or 30 days after study 23)Hamilton depression Rating Scale ( 17 ) score above 7 points. 24)History of blood phobia. Subjects whom the investigator deems necessary to exclude.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: pilot study group
|
Aripiprazol orodispersible tablets 10mg
|
Experimental: group 1 (under fasting condition)
|
Aripiprazol orodispersible tablets 10mg
Aripiprazole Orally disintegrating tablets 10mg
|
Experimental: group 2 (under fasting condition)
|
Aripiprazol orodispersible tablets 10mg
Aripiprazole Orally disintegrating tablets 10mg
|
Experimental: group 3 (under fed condition)
|
Aripiprazol orodispersible tablets 10mg
Aripiprazole Orally disintegrating tablets 10mg
|
Experimental: group 4 (under fed condition)
|
Aripiprazol orodispersible tablets 10mg
Aripiprazole Orally disintegrating tablets 10mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic parameter: Cmax
Time Frame: day 54
|
Bioequivalence based on Peak Plasma Concentration (Cmax) under fasting and fed condition
|
day 54
|
Pharmacokinetic parameter: AUC
Time Frame: day 54
|
Bioequivalence based on Area under the plasma concentration versus time curves (AUC) under fasting and fed condition
|
day 54
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: up to day 54
|
To observe the type, incidence and severity of adverse events in the study.
|
up to day 54
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Aripiprazole
Other Study ID Numbers
- KH716-E01-CRP-1.1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bioequivalence
-
Pharmtechnology LLCRecruitingBioequivalenceRussian Federation
-
Emzor Pharmaceutical Industries LimitedNot yet recruiting
-
Pharmtechnology LLCClinPharmInvest, LLCNot yet recruitingBioequivalenceRussian Federation
-
Indiana UniversityFood and Drug Administration (FDA)Completed
-
AstraZenecaCompletedBioequivalenceUnited States
-
Future University in EgyptCompleted
-
Cross Research S.A.Zambon SpACompleted
-
Laboratorios Andromaco S.A.Completed
-
Emzor Pharmaceutical Industries LimitedUnknown
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
Clinical Trials on abilify
-
The Hospital for Sick ChildrenCompleted
-
Novartis PharmaceuticalsCompletedStudy of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungUnited States, Belgium, Germany, France, Spain, Israel
-
Genuine Research Center, EgyptP&C Labs, EgyptCompleted
-
Otsuka Pharmaceutical Development & Commercialization...Completed
-
University of Sao PauloUnknownSchizophrenia or Schizoaffective DisorderBrazil
-
The University of Hong KongRecruitingAnxiety Depression | Schizophrenia and Related DisordersHong Kong
-
Inje UniversityUnknownSchizophreniaKorea, Republic of
-
Indonesia UniversityRecruitingSepsis | Bacteriuria | Urinary Tract Infections | Prostate Cancer | Perioperative Complication | Prostate BiopsyIndonesia
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedSchizophreniaBelgium, Bulgaria, Canada
-
Korea Otsuka Pharmaceutical Co., Ltd.RecruitingDepression, BipolarKorea, Republic of